[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349572-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349572-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","menopausal-hormone-therapy-and-comprehensive-postmenopausal-care-in-gynecologic-cancer-survivors-a-position-paper-from-the-figo-committee-on-women-at-menopausal-age","Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors - A position paper from the FIGO Committee on Women at Menopausal Age","","Recent advances in cancer screening, diagnosis, and treatment have improved survival for women with gynecologic cancers, but many survivors live long enough to experience treatment-related menopause. Menopausal symptoms including vasomotor complaints, genitourinary syndrome, sexual dysfunction, sleep issues, and risks from estrogen deficiency can substantially diminish quality of life. Despite more survivors, clinicians often face uncertainty because recurrence concerns and perceived hormone safety lead to inconsistent, inadequate care. This position paper reviews evidence and guidance on menopausal hormone therapy (MHT) after vulvar, vaginal, cervical, uterine, and ovarian cancers, considering tumor histology, stage, and hormonal sensitivity. Evidence suggests systemic MHT may be appropriate for carefully selected survivors of non–hormone-dependent cancers, while hormone-sensitive tumors generally warrant avoidance of systemic MHT; local vaginal hormones and non-hormonal strategies remain central. The paper also highlights resource-aware approaches to support equitable survivorship care, especially in low- and middle-income countries, to improve personalized, safe decisions and long-term well-being.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/menopausal-hormone-therapy-and-comprehensive-postmenopausal-care-in-gynecologic-cancer-survivors-a-position-paper-from-the-figo-committee-on-women-at-menopausal-age/349572/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/menopausal-hormone-therapy-and-comprehensive-postmenopausal-care-in-gynecologic-cancer-survivors-a-position-paper-from-the-figo-committee-on-women-at-menopausal-age/349572.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",18,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is menopause management important in gynecologic cancer survivorship care?","Question",{"text":63,"@type":64},"Survivorship care aims to reduce long-term treatment effects and improve quality of life. For women treated for gynecologic cancers, managing menopausal symptoms is increasingly recognized as a vital survivorship component.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What menopause symptoms are specifically discussed as affecting survivors?",{"text":68,"@type":64},"The paper highlights vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long-term risks related to estrogen deficiency as major quality-of-life impacts.",{"name":70,"@type":61,"acceptedAnswer":71},"When might systemic menopausal hormone therapy be considered for survivors?",{"text":72,"@type":64},"Current evidence suggests systemic MHT may be suitable for carefully chosen survivors with non–hormone-dependent gynecologic cancers, including most vulvar, vaginal, cervical, and epithelial ovarian cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349572,1790185705,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10. 1002/ijgo.71188  \nS PE C IA L A RT I C L E  \nMenopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors:  \nA position paper from the FIGO Committee on Women at Menopausal Age  \nAgnaldo Lopes da Silva-Filho1,2  | Suvarna Khadilkar2,3,4 | Hema Divakar5,6 | Chiara Benedetto2,7 | Andrea R. Genazzani2,8 | Diana Ramos2,9,10,11 | Elizabete Argale2,12 | Enrique Herrera2,13 | Martha Hickey2,14  \n1Department of Gynecology and Obstetrics, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil  \n2FIGO Committee on Women at Menopausal Age, FIGO, London, UK 3Gynecology and Obstetrics Department, Bombay Hospital Institute of Medical Sciences, Mumbai, India  \n4Bombay Hospital Medical Research Center, Mumbai, India  \n5FIGO Division of Well Woman HealthCare, FIGO, London, UK 6Divakar Specialty Hospital, Bengaluru, Karnataka, India  \n7Sant'Anna University Hospital, Torino, Italy  \n8 Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy 9California Surgeon General, Sacramento, California, USA  \n10 Keck University of Southern California School of Medicine, California, USA 11Women's Preventive Services Initiative Implementation Committee, American College of Obstetricians and Gynecologists (ACOG), Washington D.C, Maryland, USA  \n12Department of Obstetrics and Gynecology, Riga Stradins University, Riga, Latvia  \n13 Department of Obstetrics and Gynecology; Coordinator, Area of Endocrinology, Gynecology and Human Reproduction, Universidad del Valle, Cali, Colombia  \nAbstract  \nRecent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment-related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long-term risks from estrogen deficiency can seriously impact quality of life. Despite increased survival, managing menopausal symptoms remains difficult, as concerns about cancer recurrence and hormone therapy safety often result in inconsistent or insufficient treatment. This article explores clinical considerations for menopausal hormone therapy (MHT) in women with a history of gynecologic cancer. It reviews evidence on the safety of MHT after vulvar, vaginal, cervical, uterine, and ovarian cancers, providing an overview of tumor histology, stage, and hormonal sensitivity. It also synthesizes observational studies, systematic reviews, and international guidelines to help clinicians deliver menopausal care to cancer survivors. Current evidence suggests that systemic MHT may be suitable for carefully chosen survivors of non–hormone-dependent gynecologic cancers, including most vulvar, vaginal, cervical, and epithelial ovarian cancers. Patients with hormonally sensitive tumors should generally avoid systemic MHT, while local vaginal hormonal administration and non-hormonal options remain important in these cases. Given the disproportionate burden of gynecologic cancers in low- and middle-income countries, where younger women face increased risks of treatment-induced menopause and limited survivorship resources, this paper emphasizes context-specific, resource-aware strategies to promote equitable care. By enhancing personalized and evidence-based decision-making, we aim to improve quality of life for women during menopause after cancer treatment, while ensuring safe, fair, and widely applicable survivorship approaches.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.  \n1152  \n da SILVA-FILHO et al.  \n14De","cbCaisVzQppTUwRX","https://ap.wps.com/l/cbCaisVzQppTUwRX","pdf",2611919,21,"English","# Introduction\n## Survivorship care and menopausal symptom management\n# Menopausal hormone therapy after gynecologic cancer (position paper overview)","[{\"question\":\"Why is menopause management important in gynecologic cancer survivorship care?\",\"answer\":\"Survivorship care aims to reduce long-term treatment effects and improve quality of life. For women treated for gynecologic cancers, managing menopausal symptoms is increasingly recognized as a vital survivorship component.\"},{\"question\":\"What menopause symptoms are specifically discussed as affecting survivors?\",\"answer\":\"The paper highlights vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long-term risks related to estrogen deficiency as major quality-of-life impacts.\"},{\"question\":\"When might systemic menopausal hormone therapy be considered for survivors?\",\"answer\":\"Current evidence suggests systemic MHT may be suitable for carefully chosen survivors with non–hormone-dependent gynecologic cancers, including most vulvar, vaginal, cervical, and epithelial ovarian cancers.\"}]","Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors - A position paper from the FIGO Committee on Women at Menopausal Age | PDF",1790084358,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a814536a3cd8202675dfdbbce5632537.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb95d10c61817637f294e0aed7fb9242.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afb91f7c270a0ede43c2bf9cbc9cc987.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83dbc0a64f09cb8d0b75b1c4c18a45dd.webp",980,1287]